ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong
· Delayed Price · Currency is HKD
13.24
-0.72 (-5.16%)
Jun 13, 2025, 4:08 PM HKT
HKG:1541 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -315.86 | -379.46 | -402.89 | -732.95 |
| Depreciation & Amortization | 20.68 | 22.58 | 17.62 | 13.18 |
| Loss (Gain) From Sale of Assets | - | - | - | -0.56 |
| Asset Writedown & Restructuring Costs | 27.4 | - | - | - |
| Loss (Gain) From Sale of Investments | -14.15 | -1.76 | - | -1.6 |
| Stock-Based Compensation | 34.21 | 71.64 | 103.83 | 34.02 |
| Other Operating Activities | -5.45 | -5.24 | 20.69 | 521.45 |
| Change in Accounts Receivable | 0.02 | 0.03 | -0.03 | 0.01 |
| Change in Accounts Payable | 27.57 | 6.36 | 4.88 | 7.65 |
| Change in Unearned Revenue | 32.9 | - | - | - |
| Change in Other Net Operating Assets | 64.64 | -81.71 | 17.21 | -31.74 |
| Operating Cash Flow | -128.04 | -367.55 | -238.71 | -190.54 |
| Capital Expenditures | -10.4 | -2.69 | -23.22 | -40.7 |
| Sale of Property, Plant & Equipment | - | - | - | 0.58 |
| Investment in Securities | 40.72 | -303.37 | - | 23.65 |
| Other Investing Activities | 7.63 | 11.21 | 23.27 | -92.25 |
| Investing Cash Flow | 37.95 | -294.85 | 0.05 | -108.72 |
| Short-Term Debt Issued | - | - | - | 0.01 |
| Long-Term Debt Issued | 175.78 | 79.96 | - | - |
| Total Debt Issued | 175.78 | 79.96 | - | 0.01 |
| Short-Term Debt Repaid | - | - | - | -0.01 |
| Long-Term Debt Repaid | -125.8 | -26.21 | -5.8 | -4.77 |
| Total Debt Repaid | -125.8 | -26.21 | -5.8 | -4.78 |
| Net Debt Issued (Repaid) | 49.98 | 53.76 | -5.8 | -4.77 |
| Issuance of Common Stock | 215.94 | 307.79 | 189.57 | 800.98 |
| Other Financing Activities | -6.99 | -30.51 | -4.39 | -3.17 |
| Financing Cash Flow | 258.93 | 331.04 | 179.38 | 793.03 |
| Foreign Exchange Rate Adjustments | 1.79 | 3.14 | 26.17 | -9.12 |
| Miscellaneous Cash Flow Adjustments | -0.01 | - | - | - |
| Net Cash Flow | 170.62 | -328.23 | -33.11 | 484.65 |
| Free Cash Flow | -138.44 | -370.25 | -261.93 | -231.24 |
| Free Cash Flow Margin | -174.06% | -4811.50% | -4603.41% | -1674.69% |
| Free Cash Flow Per Share | -0.37 | -1.02 | -0.79 | -2.68 |
| Cash Interest Paid | 3.45 | 1.52 | 0.79 | 0.89 |
| Levered Free Cash Flow | -132.07 | -193.42 | -2,538 | - |
| Unlevered Free Cash Flow | -129.92 | -192.47 | -2,537 | - |
| Change in Net Working Capital | -18.12 | 56.09 | 2,407 | - |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.